Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatl ...
pharmaphorum15h
BMS study of Opdualag in adjuvant melanoma ends in failure
Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...
Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...
CURE1d
An Expert Explains Updated Data For Patients With GU Cancers
Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at ...
Targeted Oncology1d
Post–PD-1 Data in Melanoma Offers Insight into IO Approaches
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...
Pre-Op Immunotherapy May Help Treat Aggressive Breast Cancers
The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...
Targeted Oncology2d
What Community Oncologists Should Watch for at ASCO GU 2025
ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...
Nasdaq11d
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
The CHMP recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
Cure Today17d
Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset
Opdivo (nivolumab) plus Yervoy (ipilimumab) improved progression-free survival (PFS) compared to Opdivo alone in patients with mismatch repair deficient (dMMR) or microsatellite instability-high ...